充足的睡眠时间突出了类似葡萄糖-1受体变体对HbA1c的影响:基因与环境相互作用研究
Jiahe Wei1, Hanzhang Wu1, Ying Zheng1
1Department of Big Data in Health Science, Zhejiang University School of Public Health and Department of Psychiatry, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China; The Key Laboratory of Intelligent Preventive Medicine of Zhejiang Province, Hangzhou, China.
Diabetes research and clinical practice
|November 13, 2024
概括
葡萄糖类-1受体 (GLP1R) 激动剂与足够的睡眠相结合,显著改善了血糖控制. 这种组合可以降低高血糖和高HbA1c,为控制血糖水平提供更好的好处.
科学领域:
- 遗传学和个性化医学
- 代谢健康 代谢健康
- 药物基因组学 药物基因组学
背景情况:
- 葡萄糖类-1受体 (GLP1R) 激动剂和生活方式的改变是控制血糖的关键.
- GLP1R激动剂和生活方式因素对血糖特征的综合影响仍未得到充分探索.
研究的目的:
- 研究GLP1R-rs10305492变体和生活方式因素 (饮食,体育活动,睡眠,时间型) 在葡萄糖和HbA1c水平上的基因环境相互作用.
- 评估GLP1R激素和生活方式修改的协同效应,以改善血糖控制.
主要方法:
- 基因与环境相互作用研究,使用英国生物库数据 (n=263,846).
- 分析GLP1R-rs10305492变体与饮食,体育活动,睡眠时间和时间型相结合.
- 线性回归模型用于评估对葡萄糖和HbA1c的影响.
主要成果:
- 当GLP1R-rs10305492-AA/AG基因型与健康生活方式因素相结合时,与较低的葡萄糖和HbA1c相关.
- 观察到rs10305492变体和足够的睡眠时间之间对HbA1c.有显著的协同效应.
- 充足的睡眠 (7-8小时) 放大了GLP1R激动剂的HbA1c降低作用,降低了高血糖风险26%,高HbA1c降低了22%.
结论:
- 将GLP1R激动剂与充足的睡眠相结合,为血糖控制提供了附加的好处.
- 这种基因与生活方式的相互作用凸显了糖尿病管理中个性化策略的潜力.
- 充足的睡眠时间是一个重要的生活方式因素,可以提高GLP1R激动剂治疗的疗效.
相关概念视频
Glucagon-like Receptor Agonists
300
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
300
Hypoglycemia and Glucagon
152
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
152
Hormones Regulating Blood Glucose
3.1K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
3.1K
Dipeptidyl Peptidase 4 Inhibitors
172
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
172
Glucose Homeostasis: Regulation of Blood Glucose
1.4K
Carbohydrates consumed through foods are converted into glucose, a crucial energy source for the body. In the prandial state, high blood glucose levels stimulate the secretion of insulin from the pancreas. Insulin inhibits hepatic glucose production and stimulates glucose uptake and metabolism by muscle and adipose tissue. The excess glucose is converted into glycogen and stored in the liver and muscles.
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
1.4K
Insulin: Dosing Regimen and Adverse Effects
146
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
146


